Study Objectives. Identify prescribing trends for opioid use in non-malignant chronic pain (NMCP) from the National Ambulatory Medical Care Survey (NAMCS). Determine predictors of opioid use based on patient-specific factors.
Introduction
Currently in the United States, the incidence of chronic pain has grown to affect an estimated 100 million people and has been targeted as a significant public health concern [1] Under the indiscriminate classification of chronic pain is the more specific, yet still broad classification of nonmalignant chronic pain (NMCP), which is defined as pain not related to cancer that persists beyond the time of expected healing and may last from weeks to years [2, 3] . A study conducted by the American Pain Society, American Academy of Pain Medicine, and Janssen Pharmaceuticals reported that over 40% of patients with chronic pain stated that their pain was uncontrolled [4] . While pain is one of the most common reasons for physician office visits, it is often poorly understood and inadequately treated [5] . Serious consequences of untreated chronic pain include but are not limited to excessive health care expenditures, significant social costs in the form of lost productivity, lost wages, and impaired social relationships, and decreased patient quality of life with heightened risks of affected patients developing depression or suicidal ideations [5, 6] . Ultimately, these reports indicate that the gap between patients suffering with chronic pain and those who are adequately treated should be addressed.
Several guidelines focusing on the treatment of NMCP have been published over the last 10 years [5, [7] [8] [9] [10] . These guidelines recommend a multimodal approach to the treatment of NMCP including nonpharmacological therapy and optimal pharmacological therapy management including nonopioid analgesics, antidepressants, anticonvulsants, and opioids [11] . Opioids are not recommended as firstline therapy for any type of NMCP but are mentioned as potential last-line options [5, [7] [8] [9] [10] . In contrast, little evidence exists to demonstrate that use of opioids in NMCP is effective [12, 13] . In addition, reports from the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report have highlighted the significant increase in overdoses and deaths related to opioid pain relievers [14] . A Cochrane review [15] of observational case studies using long-term opioids for NMCP concluded:
The findings of this systematic review suggest that proper management of a type of strong painkiller (opioids) in well-selected patients with no history of substance addiction or abuse can lead to long-term pain relief for some patients with a very small (though not zero) risk of developing addiction, abuse, or other serious side effects. However, the evidence supporting these conclusions is weak, and longer-term studies are needed to identify the patients who are most likely to benefit from treatment.
The objectives of this study are 1) to identify prescribing trends for opioids in NMCP using the National Ambulatory Medical Care Survey (NAMCS) database, 2) to determine predictors of opioid use based on patient-specific factors, 3) to identify potential reasons why patient-specific prescribing differences may or may not exist, and 4) to identify areas to improve care associated with NMCP by increasing awareness in efforts to enhance the practice of safe pain management and positively impact chronic pain sufferers.
Materials and Methods
The National Ambulatory Medical Care Survey
The National Ambulatory Medical Care Survey (NAMCS) examines office visits from a sample of office-based physicians throughout the United States. It is conducted by the Division of Health Care Statistics, National Center for Health Statistics (NCHS), and the CDC. As previously reported, the NAMCS data, gathered from 2000 to 2007, were used to explore the treatment trends in a national sample of patients with common NMCP conditions [16] . Patient-specific information was obtained from the office visit forms and included demographics, insurance information, reason for visit, diagnoses, medication(s) prescribed, and nonmedication services recommended. Up to eight medications were recorded on the physician forms. Medications were identified based on a unique NCHS-assigned, five-digit code applied to each entry mentioned in the NAMCS data set.
Every visit was assigned a weight to produce nationally representative estimates. All statistics were analyzed using a multistage estimation procedure in order to produce generalizable results that are reflective of the entire US population. The publicly available online documents [17] provide further details on the NAMCS sampling and weighting methods.
Study Design
This cross-sectional study utilized the data obtained from NAMCS to examine the differences in opioid prescribing patterns based on age, gender, ethnicity, pain diagnosis, number of total medications, region of prescribing, payment type, physician specialty, and patient relationship with provider. These samples were analyzed to determine reported opioid prescribing habits and factors predicting opioid prescribing. The NAMCS utilizes a multistage probability design; detailed information can be found on the NAMCS website [17] .
Guidelines were selected as a basis for determining appropriate treatment of NMCP. These included the following: the Institute for Clinical Systems Improvement (ICSI) [7] , the American Pain Society and American Academy of Pain Medicine (APS-AAPM) [8] , the Wisconsin Medical Society (WMS) [9] , and the American Society of Interventional Pain Physicians (ASIPP) [10] . These guidelines were selected to identify a representative selection of recommendations based not only the type of pain diagnosed, but also because they recommended a multimodal treatment with a broad range of pharmacological as well as nonpharmacological therapies. Opioids included morphine, codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, oxycodone, propoxyphene, and the opioidlike agent tramadol. In addition, long-acting formulations and combination opioid/analgesics with acetaminophen, aspirin, and ibuprofen were included in the opioid drug class category using the NCHS-assigned, five-digit codes [9, 17] .
Study Population
The database included patients treated in US outpatient settings from 2000 to 2007, and the study population included patients age 18 years and older with NMCP. A Opioids for Nonmalignant Chronic Pain in Outpatient Settings diagnosis of NMCP was determined based on ICD-9 codes. The category, "major reason for visit," was limited to a classification of "chronic problem-routine" or "chronic problem-flare" in order to attempt to narrow the visit to be related to chronic pain and avoid visits related to acute pain. Using ICD-9 codes, diagnoses related to malignancy or neoplasm were excluded in attempts to eliminate malignant pain.
Chronic pain indications were further divided into five classifications: neuropathic, inflammatory, muscle, mechanical/compressive, and general chronic pain. The first four classifications were taken from classifications outlined by the ICSI guidelines [7] and had established corresponding ICD-9 codes. Prior to data analysis, a fifth classification of "general chronic pain" was identified and included based on ICD-9 codes. Patient visits were categorized by geographic region based on NAMCS classifications [17] .
Statistical Analysis
All variables in the study were coded prior to statistical analysis, and all analyses were weighted using NAMCS sampling weights. Descriptive bivariate and multivariate analyses of data were conducted using STATA 11.0 (College Station, TX, USA) software. The unit of analysis was the individual patient visit. Data was stratified according to patient characteristics, physician specialty, and medications prescribed. Descriptive statistics (mean, median, standard deviation, frequencies, and percentages) for all study variables were performed on weighted and unweighted data before hypothesis testing. Bivariate analyses between dependent and independent variables were conducted utilizing weighted two-way contingency table analysis. The Wald statistic resulting from the weighted two-way contingency table analysis was recommended as the summary statistic for bivariate and multivariate complex survey data analysis, accounting for the survey design [18, 19] . Significant variables (at 0.05 cutoffs) from bivariate analyses were included in the multivariate weighted logistic regression models to examine potential predictors of chronic pain treatments. If variables were considered nonsignificant in the bivariate analysis, they were not included in the multivariate analysis. Data was analyzed, de-identified, and provided by the CDC; thus this study was institutional review board waived.
Results

Study Population
The characteristics of the study population can be found in Table 1 . The study population included 690,205,290 weighted visits between the years of 2000 and 2007 with NMCP.
As reported previously, females represented 62.84% of the population. However, this was not considered statistically significant in the bivariate analysis; thus it was not included in the multivariate analysis [16] . The average age of the overall patient population was 53 years. The majority of patients were diagnosed with general chronic pain (64.15%), followed by inflammatory (16.24%), mechanical/compressive (13.97%), musculoskeletal (4.32%), and neuropathic (3.29%). Most patients were taking less than five total medications (70.80%) [16] . Figure 1 details the percentage of patients diagnosed within each chronic pain category as well as the percentage of patients receiving opioid pain relievers (OPRs) within each pain type. Of the 690 million weighted visits recorded, opioids were prescribed for the treatment of NMCP in 14.3% of patient encounters. Other medication therapies prescribed included: analgesics/nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, tricyclic antidepressants, other antidepressants, and topical lidocaine. Nonmedication treatments recorded included diet/nutrition regimens, mental health/stress management, psychotherapy, exercise, physical therapy, complementary alternative medicine, and weight loss [16] . Table 2 outlines the multivariate analysis evaluating factors associated with reported opioid prescribing. The age groups 35 to 49 years and 65 years and older, Hispanic ethnicity, having a specific pain diagnosis rather than general chronic pain, having five or more medications, payment source, patient relationship to provider, physician type, and the southern prescribing region were all determined significant variables in reported opioid prescribing habits. The most commonly reported opioid was the combination opioid/analgesic hydrocodone and acetaminophen (35%). Other commonly reported opioids included oxycodone and acetaminophen (13%), tramadol, immediate-and sustained-release formulations (12%), propoxyphene and acetaminophen (12%), which was removed from the US market in 2010, and oxycodone immediate-release and sustained-release formulations (9%).
Reported Opioid Prescribing Habits
Discussion
Among opioid users in this population, differences were noted. These differences are difficult to interpret based on the complexity of treating NMCP and the challenges of determining appropriate opioid prescribing. Some differences among the population may indicate appropriate approaches to prescribing opioid therapy. Factors such as 2.69-fold higher opioid use in patients having five or more medications may signal a stepped therapy approach in complex patients incorporating adequate trials of firstline treatments and concurrent use of nonopioid analgesics and reflect appropriate use of opioid therapy as last-line treatment based on guidelines [7] [8] [9] [10] . Higher rates of reported opioid use in established patients compared with new patients may also support rational opioid use with the importance of establishing trusting physician-patient relationships, follow-up and monitoring in patients using opioids, or ensuring that new patients have completed an adequate trial of firstline options such as nonopioid analgesics prior to prescribing opioids.
In contrast, other differences reported may signal gaps and/or inconsistencies in opioid prescribing. Hispanics reporting chronic pain were 30% less likely to receive OPRs as compared with other ethnicities. This could be due to a lack of insurance coverage or ability to pay. It could also be due to a possible language and/or cultural barriers, resulting in underreporting of pain and instilling more physician fear concerning their patients' ability to safely take opioids. Another study evaluating analgesic prescribing in US emergency rooms showed that Hispanics and blacks were also significantly less likely than whites to receive opioids [20] . Other literature reports that Hispanics were less likely than white patients to receive any pain medication and more likely to receive lower doses of pain medication or NSAIDs instead of opioids, despite comparative or higher pain scores [21] . Similarly, the CDC report [14] showed that Hispanics were less likely than non-Hispanic whites, blacks, and American Indians or Alaskan natives to die from drug overdose of OPRs, which may be related to less usage of opioids by Hispanics.
The ICD-9 code "general chronic pain" accounted for the majority of diagnoses reported at visits, at 64.15%. These patients were 57% less likely than patients with specific types of chronic pain to receive an opioid. This could be explained by a few different conjectures. A possibility is that this classification was chosen due to a lack of time or ease of use of the ICD-9 code, or the designation of "general chronic pain" was chosen because patients exhibited multiple different types of chronic pain. Another plausible reason could be that the etiology of pain was unknown. Because such a high percentage of diagnoses were categorized as "general chronic pain," an accurate evaluation of appropriate opioid prescribing for NMCP is especially challenging, and the reasons this population had a lower rate of OPRs warrants further investigation.
Patients with Medicare, Medicaid, and other insurance were significantly more likely to be prescribed opioids than those with private insurance. One possible reason for this is that patients with private insurance may be more able to afford several newer nonopioid treatments that are only available as brand name. These nonopioid agents, called adjuvant treatments, are recommended in the guidelines before the use of opioids [7] [8] [9] [10] . A number of opioids are available as generics and are less expensive than the higher-cost adjuvants. Previous results published from this study found that adjuvant therapy accounted for 69% of the estimated total pain medication costs for this study population, with the estimated adjuvant cost of therapy reported at $12.3 billion annually compared with $3.6 billion annually for opioid therapy [22] . Therefore, physicians may select to use generic opioids before many of the higher-priced adjuvants for patients with Medicare, Medicaid, and other insurance so that patients have a better ability to afford their medications.
Differences in prescribing were also observed in regards to physician type. Patients seeing primary care physicians (PCPs) were 1.83 times more likely to report use of opioids than those visits recorded from specialty physicians. As previously reported, the proportion of visits to pain specialty physicians, which were included under the specialty physician category in this study, were so small (0.12% of the NAMCS NMCP populations) that it was not possible to determine if opioids were reported at a higher or lower rate than other physician specialties or PCPs [16] .
Visits for patients age 35 to 49 years were 1.47 times more likely to report opioids than patient visits for those age 18 to 34 years. Interestingly, according to the CDC [14] , the age group with the largest number of opioidrelated deaths is patients age 45 to 54 years. Therefore, the age group with the highest risk of opioid-related deaths falls into the age group in the NAMCS NMCP population who were more likely to be prescribed opioids (age 45 to 49 years), whereas the NAMCS age group of 50 to 64 years was less likely (0.88, 95% CI ¼ 0.69 to 1.13) to be prescribed opioids in the NAMCS NMCP results, although this is not statistically significant. The higher use in the 35 to 49 age group may signal a specific population where closer screening and monitoring of opioid use may be warranted to improve safe use and possibly reduce opioid-related deaths.
In contrast, patient visits for those age 65 years and older where chronic pain conditions are more prevalent were 61% less likely to receive prescriptions for opioids compared with those age 18 to 34 years [23, 24] .
Evidence is lacking to suggest when opioid use in older populations may be appropriate or when its risks outweigh its benefits. However, the differences identified in this study may illustrate a lack of comfort or increased concern in using opioids in older populations. Several studies, along with recommendations from the American Geriatric Society (AGS) and International Expert Panel, support the judicious use of opioids in the elderly [25] [26] [27] [28] . In addition, the AGS recommends that opioids be considered over the use of NSAIDs for patients with moderate to severe pain, pain-related functional impairment, or diminished quality of life due to pain [26] .
Another difference in opioid prescribing was found in prescribing based on region. The results indicated patient visits in the Southern region of the United States were 1.36 times more likely than those in the Northeast region to list treatment with OPRs. This incidence of increased OPR prescribing shows a correlation with CDC [29] reports of increased OPR prescribing in southern states and a higher rate in the number of opioid-related deaths in the Southern region [14] . The CDC [14] reported that the highest OPR sales rates in 1999 to 2008 were clustered in the Southeast and Northwest. Only six of these 17 southern states (Texas, Mississippi, Virginia, Maryland, District of Columbia, Georgia) showed a lower overall drug overdose death rate than the national rate; thus the majority (11 states) had a higher drug overdose death rate than the national rate [14] , possibly correlating with the increase in reported opioid prescribing in this region [29] . These death rates, however, included both prescription and illicit drugs. Further assessment of regional variations in prescribing factors that may impact the use of opioids is warranted. These may include the identification of potential differences in practice attitudes and approaches, including compassionate and/or Figure 1 Percent of study population with each pain type and percent of patients prescribed opioids within each pain type [16] .
aggressive prescribing of opioids for chronic pain, pain management education in different US regions, and rural vs urban treatment attitudes; regional population variations may also influence regional prescribing practices regional standards of care in pain management.
The reported use of opioids in the NAMCS population as shown in Figure 2 parallels the reported dispensed prescriptions in 2007 with the combination product hydrocodone and acetaminophen ranking as the second and third top prescriptions dispensed, based on the different manufactures. Oxycodone and acetaminophen, acetaminophen with codeine, propoxyphene and acetaminophen, and tramadol all ranked in the top 200 dispensed prescriptions in 2007 [30] .
It is beyond the scope of this study to draw direct conclusions about opioid abuse based on usage patterns. However, it is hard to ignore that results from this study do parallel trends reported by the CDC [14, 29] such as higher use in the 35-to 49-year-olds corresponding with the highest opioid-related death rate and higher rates of opioid prescribing in the Southern region. Additionally, similarities are seen with national dispensing trends ranking hydrocodone and acetaminophen among the most commonly dispensed medications and numerous opioids among the top 200 list [30] . The CDC has recently released guidelines for primary care clinicians with recommendations for prescribing opioids in chronic pain [31] .
In evaluating the overall recorded use of opioids in this study population, 14.3% of these visits reported opioid use. Opioids use ranked third among reported drug classes in NMPC patients in this study, following NSAIDs at approximately 95% and other antidepressants including bupropion, duloxetine, and venlafaxine at 19.1%. Serotonin reuptake inhibitors closely followed opioids at 13.8%. When assessing opioid prevalence, there are wide variations in reported opioid use in various populations. In a national telephone survey in the United States in 2008, Kelly and colleagues [32] reported that 2.0% of adjusted prevalence patients used opioids regularly, which they estimated was approximately 4.3 million individuals; regular opioid use was defined as using opioids for five or more days of the week for four or more consecutive weeks. In 2007, Martell and colleagues [33] reviewed 11 studies and found opioid use in chronic back pain varying between 3% and 66%. In 2004, Caudill-Slosberg and colleagues [34] reported that the use of opioids for chronic pain increased from 8% to 16% from 1980 to 2000 based on patient visits with musculoskeletal pain in the NAMCS database. Daubresse and colleagues [35] reported use of opioids from the NAMCS database from 2000 to 2010 for visits with patient-reported symptoms or physicianreported diagnosis related to pain for a total of 7.8 million weighted visits records analyzed. They reported that, among all pain visits (including acute and chronic pain), opioid prescribing increased from 11.3% in 2000 to 19.6% in 2010.
Additional research is needed to determine appropriate use of opioids in NMCP populations, potential gaps and disparities, if increased use in certain populations correlates with opioid-related deaths, and if opioid abuse is more likely to occur in certain populations such as acute pain compared with chronic pain populations. 
Limitations
There are limitations to this study. As previously reported, the high proportion of Caucasian patients included in the analysis could disproportionately represent that population over other minority populations [16] . The ICD-9 coding of chronic pain could also pose a limitation to the study. Our study population included visits that had an NMCP diagnosis listed as one of the top three reasons for the visit, so it would not identify chronic pain in patients if an ICD-9 code for chronic pain was not listed as one of the top three reasons for the visit. Another limitation is that some visits were coded with multiple pain diagnoses. The NAMCS database presents a limitation in the fact that it only allows the entry of six to eight medications depending on the year surveyed; thus the full medication regimens of some patients may not be represented. The NAMCS database also does not record the quantity or frequency of use of medications. Patient medication compliance is also not recorded or assessed with this database. A final limitation involves the guidelines utilized to assess proper opioid prescribing. Not every guideline classifies types of pain the same way or recognizes every type of pain that was included in the ICD-9 codes. These guidelines also are often based on expert panel consensus rather than substantial scientific evidence for the efficacy and safety of opioids in NMCP.
Conclusion
The NAMCS data from 2000 to 2007 show that opioids were prescribed in 14.3% of the population and not prescribed consistently. Differences exist between those prescribed and not prescribed opioids. These differences show that patients age 65 years or older, patients of Hispanic ethnicity, and patients with private insurance were prescribed opioids less frequently, while patients with five or more medications, established patients, patients with the ICD-9 code of "general chronic pain," patients with publicly funded health insurance, patients with PCP visits, patients between age 35 to 49 years, and those who live the Southern region were more likely to receive opioid prescriptions for chronic noncancer pain. The paucity of evidence for using opioids in chronic pain complicates physicians' ability to determine appropriate use in the NMCP population. The results from this study, paired with increased education and further research regarding the appropriate prescribing and monitoring of opioids, may help enhance awareness, diminish treatment disparities, and improve safe and appropriate use of opioids in the NMCP population. 
